vs
林德（LIN）与STRATA Skin Sciences, Inc.（SSKN）财务数据对比。点击上方公司名可切换其他公司
林德的季度营收约是STRATA Skin Sciences, Inc.的945.0倍（$8.8B vs $9.3M），林德同比增速更快（8.2% vs -3.0%），林德自由现金流更多（$898.0K vs $-551.0K），过去两年STRATA Skin Sciences, Inc.的营收复合增速更高（17.3% vs 3.1%）
林德是全球知名跨国化工企业，按市场份额及营收计为全球最大工业气体供应商。公司1879年由德国科学家、工程师卡尔·冯·林德在德国威斯巴登创立，现总部位于英国沃金，在爱尔兰注册，2018年由原林德股份公司与1907年在美国成立的普莱克斯合并组建。
STRATA Skin Sciences是一家美国医疗器械企业，专注于设计、开发并商业化推出非侵入式检测工具，供皮肤科医生在进行黑色素瘤皮肤检查时获取更多辅助诊断信息。
LIN vs SSKN — 直观对比
营收规模更大
LIN
是对方的945.0倍
$9.3M
营收增速更快
LIN
高出11.2%
-3.0%
自由现金流更多
LIN
多$1.4M
$-551.0K
两年增速更快
SSKN
近两年复合增速
3.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.8B | $9.3M |
| 净利润 | — | $58.0K |
| 毛利率 | 48.5% | 61.8% |
| 营业利润率 | 27.8% | 5.3% |
| 净利率 | — | 0.6% |
| 营收同比 | 8.2% | -3.0% |
| 净利润同比 | — | 101.3% |
| 每股收益（稀释后） | $3.98 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LINSSKN
| Q1 26 | $8.8B | — | ||
| Q4 25 | $8.8B | $9.3M | ||
| Q3 25 | $8.6B | $6.9M | ||
| Q2 25 | $8.5B | $7.7M | ||
| Q1 25 | $8.1B | $6.8M | ||
| Q4 24 | $8.3B | $9.6M | ||
| Q3 24 | $8.4B | $8.8M | ||
| Q2 24 | $8.3B | $8.4M |
净利润LINSSKN
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $58.0K | ||
| Q3 25 | $1.9B | $-1.6M | ||
| Q2 25 | $1.8B | $-2.6M | ||
| Q1 25 | $1.7B | $-2.1M | ||
| Q4 24 | $1.7B | $-4.6M | ||
| Q3 24 | $1.6B | $-2.1M | ||
| Q2 24 | $1.7B | $-91.0K |
毛利率LINSSKN
| Q1 26 | 48.5% | — | ||
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% |
营业利润率LINSSKN
| Q1 26 | 27.8% | — | ||
| Q4 25 | 23.0% | 5.3% | ||
| Q3 25 | 27.5% | -16.9% | ||
| Q2 25 | 27.7% | -30.1% | ||
| Q1 25 | 26.9% | -25.0% | ||
| Q4 24 | 27.4% | -44.7% | ||
| Q3 24 | 25.0% | -18.2% | ||
| Q2 24 | 26.4% | -5.7% |
净利率LINSSKN
| Q1 26 | — | — | ||
| Q4 25 | 17.5% | 0.6% | ||
| Q3 25 | 22.4% | -23.4% | ||
| Q2 25 | 20.8% | -33.6% | ||
| Q1 25 | 20.6% | -31.2% | ||
| Q4 24 | 20.8% | -47.6% | ||
| Q3 24 | 18.5% | -23.6% | ||
| Q2 24 | 20.1% | -1.1% |
每股收益（稀释后）LINSSKN
| Q1 26 | $3.98 | — | ||
| Q4 25 | $3.28 | $0.14 | ||
| Q3 25 | $4.09 | $-0.36 | ||
| Q2 25 | $3.73 | $-0.62 | ||
| Q1 25 | $3.51 | $-0.51 | ||
| Q4 24 | $3.61 | $-2.01 | ||
| Q3 24 | $3.22 | $-0.51 | ||
| Q2 24 | $3.44 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.0B | $7.9M |
| 总债务越低越好 | $24.7B | $15.3M |
| 股东权益账面价值 | $40.1B | $2.9M |
| 总资产 | $86.3B | $30.5M |
| 负债/权益比越低杠杆越低 | 0.62× | 5.28× |
8季度趋势，按日历期对齐
现金及短期投资LINSSKN
| Q1 26 | $4.0B | — | ||
| Q4 25 | $5.1B | $7.9M | ||
| Q3 25 | $4.5B | $7.1M | ||
| Q2 25 | $4.8B | $6.0M | ||
| Q1 25 | $5.3B | $6.5M | ||
| Q4 24 | $4.8B | $7.3M | ||
| Q3 24 | $5.2B | $7.1M | ||
| Q2 24 | $4.6B | $5.5M |
总债务LINSSKN
| Q1 26 | $24.7B | — | ||
| Q4 25 | $20.7B | $15.3M | ||
| Q3 25 | $18.6B | $15.3M | ||
| Q2 25 | $19.7B | $15.0M | ||
| Q1 25 | $17.6B | $15.0M | ||
| Q4 24 | $15.3B | $15.0M | ||
| Q3 24 | $17.5B | $15.0M | ||
| Q2 24 | $16.9B | $15.0M |
股东权益LINSSKN
| Q1 26 | $40.1B | — | ||
| Q4 25 | $38.2B | $2.9M | ||
| Q3 25 | $38.6B | $1.3M | ||
| Q2 25 | $38.5B | $532.0K | ||
| Q1 25 | $38.0B | $3.0M | ||
| Q4 24 | $38.1B | $5.0M | ||
| Q3 24 | $39.2B | $9.4M | ||
| Q2 24 | $38.2B | $9.5M |
总资产LINSSKN
| Q1 26 | $86.3B | — | ||
| Q4 25 | $86.8B | $30.5M | ||
| Q3 25 | $86.0B | $30.7M | ||
| Q2 25 | $86.1B | $29.5M | ||
| Q1 25 | $82.7B | $33.0M | ||
| Q4 24 | $80.1B | $34.9M | ||
| Q3 24 | $82.5B | $39.4M | ||
| Q2 24 | $80.2B | $38.8M |
负债/权益比LINSSKN
| Q1 26 | 0.62× | — | ||
| Q4 25 | 0.54× | 5.28× | ||
| Q3 25 | 0.48× | 11.65× | ||
| Q2 25 | 0.51× | 28.20× | ||
| Q1 25 | 0.46× | 5.04× | ||
| Q4 24 | 0.40× | 3.02× | ||
| Q3 24 | 0.45× | 1.60× | ||
| Q2 24 | 0.44× | 1.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-239.0K |
| 自由现金流经营现金流 - 资本支出 | $898.0K | $-551.0K |
| 自由现金流率自由现金流/营收 | 0.0% | -5.9% |
| 资本支出强度资本支出/营收 | — | 3.4% |
| 现金转化率经营现金流/净利润 | — | -4.12× |
| 过去12个月自由现金流最近4个季度 | $4.2B | $-4.4M |
8季度趋势，按日历期对齐
经营现金流LINSSKN
| Q1 26 | — | — | ||
| Q4 25 | $3.0B | $-239.0K | ||
| Q3 25 | $2.9B | $-64.0K | ||
| Q2 25 | $2.2B | $-1.9M | ||
| Q1 25 | $2.2B | $-550.0K | ||
| Q4 24 | $2.8B | $703.0K | ||
| Q3 24 | $2.7B | $-302.0K | ||
| Q2 24 | $1.9B | $591.0K |
自由现金流LINSSKN
| Q1 26 | $898.0K | — | ||
| Q4 25 | $1.6B | $-551.0K | ||
| Q3 25 | $1.7B | $-1.1M | ||
| Q2 25 | $954.0M | $-2.0M | ||
| Q1 25 | $891.0M | $-749.0K | ||
| Q4 24 | $1.6B | $199.0K | ||
| Q3 24 | $1.7B | $-364.0K | ||
| Q2 24 | $796.0M | $246.0K |
自由现金流率LINSSKN
| Q1 26 | 0.0% | — | ||
| Q4 25 | 17.9% | -5.9% | ||
| Q3 25 | 19.4% | -15.6% | ||
| Q2 25 | 11.2% | -26.1% | ||
| Q1 25 | 11.0% | -11.0% | ||
| Q4 24 | 18.8% | 2.1% | ||
| Q3 24 | 19.9% | -4.1% | ||
| Q2 24 | 9.6% | 2.9% |
资本支出强度LINSSKN
| Q1 26 | — | — | ||
| Q4 25 | 16.6% | 3.4% | ||
| Q3 25 | 14.8% | 14.7% | ||
| Q2 25 | 14.8% | 0.8% | ||
| Q1 25 | 15.7% | 2.9% | ||
| Q4 24 | 15.1% | 5.3% | ||
| Q3 24 | 12.8% | 0.7% | ||
| Q2 24 | 13.7% | 4.1% |
现金转化率LINSSKN
| Q1 26 | — | — | ||
| Q4 25 | 1.98× | -4.12× | ||
| Q3 25 | 1.53× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.76× | — | ||
| Q2 24 | 1.16× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LIN
暂无分部数据
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
